Cytokinetics Inc - Company Profile
Powered by
All the data and insights you need on Cytokinetics Inc in one report.
- Save hours of research time and resources with
our up-to-date Cytokinetics Inc Strategy Report
- Understand Cytokinetics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Cytokinetics Inc (Cytokinetics) discovers, develops and commercializes muscle activators and inhibitors for the treatment of muscle function disorder in cardiovascular and neuromuscular diseases. The company operates through one reportable segment. Its product pipeline consists of Omecamtiv Mecarbil, a cardiac muscle myosin activator in Phase III clinical trials for the treatment of heart failure with reduced ejection fraction (HFrEF); Aficamten (CK-274), an oral, small molecule cardiac myosin inhibitor in Phase III trials intended to reduce hypercontractility associated with hypertrophic cardiomyopathy (HCM); CK-136 (formerly AMG 594), a novel oral, small molecule cardiac troponin activator in Phase I for heart failure and other diseases; Reldesemtiv, a fast skeletal muscle troponin activator (FSTA) in Phase III for the treatment of muscle weakness, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA); CK-601, a next-generation FSTA in Preclinical Phase for the treatment of pathogenesis of neuromuscular and non-neuromuscular etiology. It is also developing additional skeletal muscle activators and muscle biology-directed products in the research phase.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D activities focus on the development of drug candidates for the treatment of muscle function disorder. It conducts muscle contractility research through its cardiac muscle contractility and skeletal muscle contractility program. Its cardiac muscle contractility program focuses on cardiac sarcomere, a basic unit of muscle contraction in the heart and the skeletal muscle contractility program focuses on the activation of the skeletal sarcomere, the basic unit of skeletal muscle contraction. It utilizes the knowledge and expertise gained through continuous exploration and development of cardiac sarcomere activators. In FY2023, the company incurred expenses of US$330.1 million on its R&D activities. Through research collaborations with Astellas, Cytokinetics advances its muscle biology programs. The company intends to advance its business by seeking patent protection for the technologies, inventions and improvements. As of December 31, 2023, the company owned or licensed 76 issued US patents, over 700 issued patents in various countries and over 480 additional pending US and foreign patent applications.
Other Break-up
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer